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Abstract 
Introduction: Previous studies have shown that gene expression can change throughout 
development,
1
 and therefore genotype-phenotype associations found in adults might not be 
observed in children of all ages. The purpose of this study was to 1) characterize the ontogeny of 
30 genes in pathways related to cholesterol synthesis and/or statin action or toxicity in pediatric 
liver samples, and 2) assess the in vitro and in vivo consequences in children of genetic variation 
in 3-hydroxy-3-methyl-glutaryl-Coenzyme A reductase (HMGCR) and heterogeneous nuclear 
ribonucleoprotein A1 (HNRNPA1), two genes implicated in altered cholesterol levels and/or 
statin response.
2,3
 
Methods: RNA and DNA were isolated from pediatric liver samples (n=62), and DNA was 
isolated from patients in the Cardiology Pharmacogenomic Repository (CPR) (n=195). For Aim 
1, the ontogeny of mRNA expression from 30 genes related to cholesterol and statin metabolism 
as measured by RNA-seq in the liver samples was assessed. For Aim 2, all postnatal samples 
were genotyped for rs1920045 (HNRNPA1) and rs3846662 (HMGCR), and genotypes were 
tested for association with either alternative splicing in vitro (liver samples) or plasma lipid 
levels in vivo (CPR). Statistical analyses on liver sample data were conducted with Kruskal-
Wallis or Wilcoxon tests with Bonferroni correction. Analysis of CPR samples was completed 
with ANOVA, Kruskal-Wallis or Wilcoxon tests with Bonferroni correction. Samples were 
stratified by race and analyses were repeated. Liver sample use was deemed non-human subjects 
research and the CPR was approved by the Pediatric IRB. 
Results: Analysis of postnatal liver samples revealed age-related changes in Ensembl-based total 
and primary mRNA transcript expression of ABCB1 (p<0.0008). Inclusion of prenatal samples 
revealed 13 additional genes with age-related expression changes during development in either 
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the Ensembl or UCSC based data. The ratios of alternative to canonical transcripts of HMGCR 
trended towards significance in the HMGCR and HNRNPA1 dominant genotype models 
(p=0.0465, 0.0470 respectively). CPR analysis suggested a relationship between HMGCR 
genotype and low-density lipoprotein cholesterol (LDL-C) or total cholesterol (TC) in African 
Americans, or HNRNPA1 genotype and TC in Caucasians, but these relationships did not 
achieve statistical significance.  
Conclusion: Although trends in age-related changes in gene expression, and genotype-
phenotype associations, were observed for several genes of interest, the number of statistically 
significant associations was limited by use of a stringent criterion for multiple testing as well as 
intra-group variability and relatively small sample sizes given the amount of variability 
observed. Until these issues are resolved in a larger number of samples, it is premature to 
conclude genotype-phenotype associations observed in adults will also be present in children at 
all ages. 
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INTRODUCTION 
Between childhood and early adulthood, significant precursors to cardiovascular disease 
(CVD), begin forming in coronary arteries.
4
 The Bogalusa Heart Study found that the presence 
of fatty streaks in coronary arteries increased in prevalence from 50% at 2 – 15 years of age to 
85% at 21 – 39 years of age, and the presence of raised fibrous plaques increased in prevalence 
from 8% to 69% during this time.
4
 Additionally, the emerging childhood obesity epidemic has 
accelerated the concern over CVD risk factor development among children.
5
  
In response, the National Heart, Lung, and Blood Institute (NHLBI) released updated 
pediatric cardiovascular health guidelines in 2011, which recommended universal lipid screening 
for children between nine and 11 years of age.
6
 Lipid lowering therapy during adolescence is one 
focus of the updated guidelines, and statins are recommended as a first-line pharmacotherapeutic 
option for children with elevated lipid levels.
6
 Statins constitute a medication class that acts 
primarily by inhibiting 3-hydroxy-3-methylglutaryl-Coenzyme A reductase (HMGCR) in the 
liver, which is the rate-limiting enzyme in endogenous cholesterol synthesis. Recently, it was 
estimated that over 200,000 children qualify for statin use in the U.S.
7
 
There are presently seven FDA-approved drugs within the statin class: atorvastatin, 
fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin.
8
 Transporters are 
involved in the import of some statins into hepatocytes.
9
 Once in the hepatocyte, statins exert 
their clinical effect on the cholesterol pathway, can be transformed by multiple enzymes into 
active or inactive forms, and are later excreted into the bile by transporter proteins.
10,11
 Due to 
the well-defined pathways involved in their pharmokinetics and pharmacodynamics, statins offer 
a unique and important opportunity to explore genetic ontogeny and variation involved with their 
disposition and molecular effect as it relates to clinical response. 
  
   
   2 
Within the medical community, there exists some concern over disrupting cholesterol 
metabolism during childhood development.
12
 Lipids and sterols are involved in neuronal 
development as well as synthesis of steroid hormones, key components of development.
12
 Statins 
have been shown to be safe and efficacious in pediatric populations; however, much of this data 
comes from studies with relatively short follow-up periods.
13
 Considering how statins are 
commonly used long-term, which could equate to decades if initiated in childhood, the safety of 
statin use during childhood and adolescence has yet to be fully determined.
13
 Initial studies have 
shown conflicting results surrounding the impact of statins on hormone levels, and neuronal 
effects, if any, may not be apparent until much later on in life.
12,13
 A study to fully address these 
concerns would likely be resource and time intensive. Surrogate endpoints, such as lipid levels 
and liver enzymes, are currently used to assess both the efficacy and safety of statins in 
children.
12
 Additional information could be gained from characterizing the genetic background 
of statin therapeutic and metabolic pathways during development. 
It is widely recognized that gene expression changes as children grow and develop;
1
 
however, the molecular-level details of this process for many genes involved in statin 
pharmacokinetics and pharmacodynamics are largely unknown. Studies on some of the most 
common drug metabolizing enzymes, cytochrome P450 (CYP) enzymes, have shown that the 
expression of these genes changes throughout childhood development.
14
 This suggests that the 
expression ontogeny of other drug metabolizing and transporting genes could also be dynamic 
and thus greatly affecting pharmacokinetics and pharmacodynamics in pediatric patients. 
Although the ontogeny of CYP enzymes has been extensively characterized, targets of statin 
action remain ontogenetically undescribed.  
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Additionally, multiple genes have been identified that may contribute to variability in 
statin response.
15
 For instance, some statins or statin metabolites have been shown to be 
substrates of a drug transporter, MDR1, encoded by the gene ABCB1,
16
 and variation within this 
gene has shown some association with response to treatment with particular statins;
17,18
 however, 
the effect may not be clinically significant.
17
 Our research team and a collaboration in the 
Netherlands have published on its hepatic ontogeny in prenatal, neonatal and a small group of 
pediatrics, yet ABCB1’s hepatic expression at different points in childhood was not fully 
investigated.
19
 An additional gene, SLCO1B1, codes for a transporter thought to import statins 
into the hepatocyte.
20
 In adults, genetic variation in this gene has been associated with increased 
plasma statin levels and clinical myopathy, yet in children it was shown to be associated with 
decreased plasma drug levels.
21,22
 Furthermore, Gryn and Hegel published a review describing 
genetic variation in dozens of genes, such as HMGCR and COQ2, which have been associated 
with statin therapy in adults
15
 and has yet to be fully investigated in the pediatric setting. 
Recently, an alternative transcript of the statin target, HMGCR, that lacks exon 13 
(HMGCRΔ13) has gained attention for its association with reduced response to statins in adults.
3
 
A variant in HMGCR, rs3846662, was associated with increased expression of HMGCRΔ13 
relative to the expression of the canonical HMGCR transcript including exon 13 (HMGCRex13) 
in Caucasian lymphoblastoid cell lines (LCLs).
23
 HMGCR has a binding motif for heterogeneous 
nuclear ribonucleoprotein A1 (HNRNPA1) in the intronic region between exons 13 and 14 
(Figure 1).
2
 HNRNPA1 has been shown to impact the alternative expression of HMGCR; 
however the relationship was not investigated in the dynamic metabolisms of children.
2
 
Additionally, it was shown that a variant upstream of HNRNPA1, rs1920045, was associated 
with altered expression of an alternative transcript of HNRNPA1 that included exon-8 
  
   
   4 
(HNRNPA1ex8) versus the canonical transcript that excluded exon 8 (HNRNPA1Δ8) (Yu, et al., 
Supplemental Figure S6-A).
2 
This splice variant, HNRNPA1ex8, in turn was hypothesized to 
increase expression of HMGCRΔ13.
2
 It is therefore hypothesized that ‘T/T’ genotype will alter 
relative HMGCRΔ13 expression. The transcript of HMGCRΔ13 may have clinical significance, 
as a relative increase in expression of the transcript has been associated with cholesterol-
lowering in response to statins, and SNP rs3846662 linked to this expression is associated with 
lipid levels in adults.
3,23,24
  
 
Figure 1. Canonical and Alternative Splicing of HMGCR (A) and HNRNPA1(B). Solid lines indicate the splicing 
pattern for the canonical transcript. Dashed lines indicate the splicing pattern for the alternative transcript.
2
 
 
Phenotypic variation due to genetic differences that have been observed in adults may 
only be apparent in children once gene pathways are fully developed. In order to determine this, 
the developmental trajectory of gene expression must be described. Additionally, genetic 
variants with known phenotypes in adults need to be studied in children to discern whether the 
phenotype-genotype associations remain consistent. The objectives of this study were to (1) 
characterize the ontogeny of mRNA expression in pediatric liver samples for a set of 30 genes in 
pathways associated with cholesterol synthesis and/or statin therapeutic response or toxicity, and 
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(2) investigate the consequences of genetic variation in HMGCR and HNRNPA1 in a pediatric 
context, both in vitro and in vivo. 
METHODS 
Tissue Repository 
Human liver tissues were obtained from two National Institute of Child Health and 
Development supported tissue repositories – the University of Maryland Brain and Tissue Bank 
for Developmental Disorders (Baltimore, MD) and the Laboratory of Human Development at the 
University of Washington (Seattle, WA), the Liver Tissue Cell Distribution System, and 
Xenotech, LLC (Lenexa, KS). The age of removal of liver samples ranged from prenatal (103 
days post-conception) to late adolescence (17 years). All individuals were deceased at the time of 
removal and the causes of death varied. The use of this repository has been deemed non-human 
subjects research by the Children’s Mercy Hospital (CMH) Pediatric Institutional Review Board 
(IRB). Characteristics of the samples used from the liver repository are described in Table 1. 
RNA and DNA were extracted from liver tissues with the Qiagen AllPrep DNA/RNA Mini Kit 
or the Qiagen AllPrep DNA/RNA/miRNA Universal Kit (Hilden, Germany) and stored at -80
o
C 
and 4
o
C, respectively.  
RNA samples for RNA-sequencing (RNA-seq) were selected based on the absence of 
documented liver disease or medications affecting the liver, representative distribution across 
developmental ages, and an RNA Quality Index (RQI) above 3. RQI is a quality measure, 
analogous to RNA Integrity Number (RIN) fom the Agilent Bioanalyzer, on a scale from zero to 
10, with 10 being considered the highest quality. The RNA was run in a microfluidic StdSens 
chip on an Experion
TM
 (Bio-Rad, Hercules, CA). 
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Table 1. Characteristics of Liver Tissue Samples (n=61). 
Characteristic N 
Age at Time of Removal 
  
 
Group 0 (prenatal) 10 
 
Group 1 (birth to <1 year) 14 
 
Group 2 (1 to ≤6 years) 16 
 
Group 3 (>6 to ≤12 years) 13 
 
Group 4 (>12 years) 8 
Sex 
    
 
Male 
  
45 
 
Female 
  
16 
Race 
    
 
Caucasian 
 
18 
 
African American 
 
8 
 
Other, Multiple, Unknown 35 
 
 
Living Repository – Cardiology Pharmacogenomics Repository (CPR) 
The Cardiology Pharmacogenomics Repository (CPR) is a living patient repository with 
DNA isolated from biospecimens (i.e. saliva, blood) of each participant, using the Sigma 
GeneElute™ Mammalian Genomic DNA Miniprep Kit (St. Louis, MO) or QIAamp
®
 DNA 
Blood Mini Kit (250) (Hilden, Germany) according to manufacturer protocols. The enrollment 
criteria include: age 0 to 26 years, patients with existing cardiac disease, patients at risk of CVD 
(i.e. abnormal lipid profile, obesity, diabetes mellitus, family history of cardiac disease), and/or 
patients receiving a cardiovascular pharmacotherapeutic. Participants were recruited from the 
nutrition, weight management, general cardiology, and preventative cardiology clinics at CMH. 
The samples were coded to protect patient privacy but could be linked back to participants’ 
Electronic Medical Records (EMR) by the Principal Investigator for retrospective chart review. 
All samples in the CPR as of February 25, 2015 (n = 195) were included in this study, except for 
one participant who had missing data on all measurements. A total of eight patients were 
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subsequently excluded: five patients who had been enrolled following cardiac transplantation 
and three who had no lipid panel documented in their EMRs prior to statin therapy (final n=186). 
The CPR was approved by the CMH Pediatric IRB. 
CPR Clinical Data Collection 
Retrospective chart review was conducted to collect values for total cholesterol (TC), 
low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), 
triglycerides, height, weight, body mass index (BMI), age (in years and months) at time of lab 
draw, and sex for each CPR participant. Information regarding documented lipid-lowering 
medication use at the time of lab draw was also collected. Lipid values were taken from the most 
recently documented lab draw up to and including the intervention visit, except one participant, 
whose lipid values after the visit were used. The BMI was taken from the intervention visit 
documentation. To get the correct age from the data for BMI percentile calculation, the month 
difference between the lipid panel date and the visit date was calculated and then added to the 
age at time of the lab. There were two participants for which this calculation could not be 
completed. This calculated age was then used for calculation of the BMI percentile. Race 
information was taken from documentation of the participant’s self-reported race at the time of 
his or her enrollment. Races were inclusive of those identifying with a Hispanic ethnicity for 
analysis (i.e. Caucasian race with non-Hispanic ethnicity was included with Caucasian race with 
Hispanic ethnicity, and the same was done for ethnically Hispanic African Americans). 
Characteristics of the CPR participants are described in Table 2. The collection of this 
information was performed with the CPR Principal Investigator, Dr. Jon Wagner, to ensure the 
most appropriate dates were selected and the correct information was recorded. 
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Table 2. Characteristics of CPR Participants (n=186). 
Characteristic                N 
Sex 
 
 
Male 
  
92 
 
Female 
  
94 
Race 
 
 
Caucasian 138 
       Hispanic Ethnicity 30 
       Non-Hispanic Ethnicity 108 
 
African American 27 
       Hispanic Ethnicity 1 
       Non-Hispanic Ethnicity 26 
 
Other, Multiple, Unknown 21 
BMI Category 
 
 
Underweight 3 
 
Normal Weight 29 
 
Overweight 26 
 Obese 126 
 
Unknown 2 
Lipid Lowering Therapy 
 
 
Fish Oil 15 
  Red Yeast Rice 1 
Clinical Characteristics (NHLBI 
“Acceptable Concentration”)
6
         Mean (SD) 
Age, years 12 (3.2) 
Baseline Total Cholesterol, mg/dL 
(<170 mg/dL) 242 (52) 
Baseline LDL Cholesterol, mg/dL 
(<110 mg/dL) 166 (52) 
Baseline HDL Cholesterol, mg/dL 
(>45 mg/dL) 47 (13) 
Baseline Triglycerides, mg/dL  
(Age 0 to 9 yrs, <75 mg/dL 
Age 10 to 19 yrs <90 mg/dL) 151 (81) 
 
RNA-seq and Bioinformatics  
RNA-seq was completed for 62 liver tissue samples from the repository. One µg total 
human liver RNA was used to generate TrueSeq Ribo-Zero libraries with the Illumina TruSeq 
Stranded Total RNA with Ribo-Zero Globin Library Prep Kit. Samples were run on the Illumina 
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HiSeq 1500 (Genomics Research Core Lab) with paired-end (2 x101), deep sequencing coverage 
(104x). 
RNA-seq reads were output in FASTQ format, and the data were organized by individual 
samples. Quality control was performed with FastQC. No sequence trimming or removal was 
performed. Two reference transcriptomes were prepared, one from the European Molecular 
Biology Laboratory (Ensembl) database and one from the University of California Santa Cruz 
(UCSC) genome database. RNA-seq Expectation Maximization (RSEM) was performed with 
Bowtie2 to index the reference transcriptomes and align the sample reads. Based on the 
maximum likelihood model, RSEM was run to assign reads to annotated transcripts and estimate 
the abundance of each transcript. In data analysis, one sample was removed as a library size 
outlier.  
Genes of interest for this study were identified from statin pharmacodynamic and 
pharmacokinetic pathways (PharmGKB),
10,11
 reviews of the pharmacogenomics of statin 
disposition and response,
15,25,26
 and genome-wide association studies of variability in cholesterol 
levels (for example Tikkanen, et al. and citations therein).
27 
The query included total and primary 
transcripts of ABCB1, AGTR1, AMPD1, APOC1, APOC2, APOE, ATP2B1, CETP, CLMN, 
CPT2, COQ2, CYP7A1, DMPK, DNAJC5B, GATM, HMGCR, HNRNPA1, HTR3B, HTR7, KIF6, 
LDLR, LPA, LPIN1, MYLIP, NOS3, PCSK9, PYGM, RYR1, SLC10A1, and SLCO1B1. This set of 
genes was analyzed for total and primary transcript mRNA expression changes associated with 
age as a categorical variable, from prenatal (103 days post-conception) to age 17 years. 
Additionally, the RNA-seq dataset was queried for mRNA expression changes associated 
with HMGCR rs3846662G>A and HNRNPA1 rs1920045C>T. The transcripts of interest were 
HMGCR transcripts including and excluding exon 13 (ENST00000287936 and 
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ENST00000343975, respectively) and HNRNPA1 transcripts including and excluding exon 8 
(ENST00000340913 and ENST00000547276, respectively). This SNP-associated gene 
expression had been previously described in LCLs.
2,23
 
Genotyping 
All postnatal DNA samples (liver and CPR) in this study were genotyped for HMGCR 
rs3846662G>A and HNRNPA1 rs1920045C>T using TaqMan
®
 SNP genotyping assays 
C__2838669_10 and C__12057681_10, respectively (LifeTechnologies, Carlsbad, CA), with 
KAPA Probe Fast qPCR Master Mix (2x) ABI Prism
®
 (KAPA Biosystems, Boston, MA) on an 
AB 7900HT Fast Real-Time PCR System (Applied Biosystems). For each reaction, 3 to 19 ng of 
DNA were used, in a total volume of 6 uL, with the exception of one sample that amplified with 
less than 0.53 ng of DNA in this volume. If amplification of a sample failed, the input DNA was 
doubled. The cycling conditions for both assays were 95
o
C, 2 min, [95
o
C, 10 sec, 60
o
C, 60 sec] 
for 45 cycles. DNA samples from the Coriell Institute for Medical Research were used as 
controls (HMGCR, G/G: NA17294, HMGCR, G/A: NA12813, HMGCR, A/A: NA12877; 
HNRNPA1, C/C: NA12882, HNRNPA1, C/T: NA17204, HNRNPA1, T/T: NA06989). Ten 
percent of samples were randomly selected and run a second time to check for consistency. For 
each marker, call rates were computed (100%) along with Hardy-Weinberg Equilibrium (HWE) 
tests by race (Table 3). 
 
 
 
Table 3. Genotype Information of Samples. AA: HMGCR G/G or HNRNPA1 C/C, AB: Heterozygous, BB: HMGCR A/A or HNRNPA1 T/T 
Gene RsID Cohort Position Alleles 
Total Genotype, 
N 
HWE       
p-value 
Cau. Genotype, 
N 
HWE       
p-value 
Af. Am. Genotype, 
N 
HWE       
p-value AA AB BB AA AB BB AA AB BB 
HMGCR rs3846662 RNA-seq Chr. 5 G>A 16 23 12 0.5091 5 8 5 0.6374 6 2 0 0.6862 
 
CPR 
  
69 76 41 0.0254 38 62 38 0.2334 21 6 0 0.5160 
HNRNPA1 rs1920045 RNA-seq Chr. 12 C>T 21 22 8 0.5809 6 9 3 0.9035 1 4 3 0.8504 
 
CPR 
  
50 87 49 0.3791 49 67 22 0.9096 0 8 19 0.3662 
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Statistical Analysis 
Association of age with gene expression measured by RNA-seq for the 30 genes of 
interest was carried out using Kruskal-Wallis tests (i.e., non-parametric ANOVA) with 
Bonferroni correction (significance: p<0.0016). Age was treated as a categorical variable and 
gene expression - in transcripts per million reads (TPM) - was continuous. Age groups were 
based on developmental stages (Group 0: prenatal, Group 1: birth to <1 year, Group 2: 1 to ≤6 
years, Group 3: >6 to ≤12 years, and Group 4: >12 years). Categorical age group analysis was 
selected over continuous age analysis to allow detection of non-linear expression changes that 
may occur during development. Gene expression was evaluated as total transcript expression and 
primary transcript expression. The most abundant transcript in the RNA-seq output was chosen 
as the primary transcript. The significance threshold with Bonferroni correction was higher for 
the primary transcript analysis because only 27 genes had more than one transcript from which to 
choose a primary transcript in the RNA-seq output for the Ensembl dataset and only 13 genes 
had more than one transcript in the UCSC dataset (p<0.0018 and p<0.0038, respectively). 
Separate analyses were performed including and excluding the prenatal samples. Pairwise 
comparisons were performed with Tukey’s HSD or Steel-Dwass tests. 
The ratios of alternative to canonical transcript expression for HMGCR and HNRNPA1 
were calculated from the measured RNA-seq transcript data and log-transformed. Associations 
of log-transformed ratios with the genotypes of interest were assessed using Wilcoxon (chi-
square approximation to the one-way test) or Kruskal-Wallis tests with Bonferroni correction. 
Both general genetic (co-dominant) and dominant genetic models were performed, and ratios of 
gene expression were viewed as continuous variables. The samples were stratified by race and all 
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analyses were repeated for the Caucasian subgroup. There was an insufficient number of African 
American samples to perform separate analyses for this subgroup. 
Associations between the genotypes (HMGCR or HNRNPA1) and lipid levels (TC, LDL-
C, HDL-C, or triglycerides) were evaluated using ANOVA with log-transformed lipid levels and 
genotype modeled with a general genetic (co-dominant) model. BMI percentiles were calculated 
from the raw BMI, sex, and age at BMI visit. These percentiles were categorized into 
underweight (<5
th
 percentile), normal (5
th
 to <85
th
 percentile), overweight (85
th
 to <95
th
 
percentile), or obese (≥95
th
 percentile) according to the guidelines from the Center for Disease 
Control (CDC). One participant was over 20 years old, and thus was classified according to the 
adult CDC guidelines. BMI was then analyzed as a categorical variable with a contingency table 
and Chi-square or Fisher’s Exact test. Due to fewer than 3 participants being classified as 
underweight, this category was excluded from the BMI analysis. Samples were stratified by race 
and all CPR analyses were repeated for Caucasians and African Americans separately using 
Kruskal-Wallis or Wilcoxon tests with Bonferonni correction. 
All statistical analysis was conducted in JMP
®
, Version 10. SAS Institute Inc., Cary, NC, 
1989-2007 or R version 3.1.2 (www.R-project.com).
28
 
RESULTS 
Hepatic Ontogeny 
The Ensembl-based total gene expression ontogeny analysis of the gene set including 
prenatal samples revealed 12 genes with expression changes significantly associated with age: 
ABCB1 (p<0.0001), APOC1 (p=0.0008), ATP2B1 (p<0.0001), CETP (p<0.0001), COQ2 
(p=0.0003), CYP7A1 (p<0.0001), DMPK (p<0.0001), HMGCR (p=0.0002), HNRNPA1 
(p<0.0001), KIF6 (p<0.0001), MYLIP (p<0.0001), and RYR1 (p=0.0005) (Table 4). In pairwise 
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comparisons for each of these genes, the expression in Group 0 (prenatal) differed from the 
expression in at least one other group (Table B1). Analysis of the transcripts aligned to the 
UCSC database showed significant age associations in the same genes as in the Ensembl 
analysis, except for COQ2 (p=0.0059) (Table 4). Two additional genes were significant in the 
UCSC-based analysis: APOC2 (p=0.0003) and LPIN1 (p<0.0001). In pairwise comparisons for 
these two genes, the expression in Group 0 (prenatal) differed from the expression in at least one 
other group (Table B1).  
The Ensembl-based primary transcript expression analysis including prenatal samples 
revealed significant associations between age and the expression of ABCB1 (p<0.0001), APOC1 
(p=0.0008), CETP (p=0.0002), CLMN (p=0.0003), COQ2 (p=0.0002), DMPK (p=0.0001), 
HMGCR (p=0.0001), HNRNPA1 (p=0.0002), KIF6 (p=0.0005), LPIN1 (p=0.0002), and MYLIP 
(p<0.0001) (Table 5). Pairwise analysis showed that Group 0 (prenatal) gene expression differed 
from the expression in at least one other age group for each of these genes (Table B2). All of 
these genes that also had primary transcripts in the UCSC-based data showed an analogous 
relationship between age and primary UCSC transcript expression, with the exception of CETP 
(p=0.1644) (Table 5). 
 Due to the different cellular environment of the prenatal liver compared to the postnatal 
liver, separate analyses were performed excluding the prenatal samples. In the Ensembl-based 
total gene expression ontogeny analysis of the 30 genes of interest, excluding prenatal samples, 
only one gene’s expression, ABCB1, showed significant association with age (p=0.0008) (Table 
4). There was an increase in ABCB1 expression during development, with Group 1 (<1 year-old) 
showing significantly different gene expression from other groups (Figure 2; Table 6). In the 
UCSC alignment, ABCB1 expression trended toward a significant relationship with age but did 
  
   
   14 
not reach significance (p=0.0024) (Figure 3). No other gene’s expression showed a significant 
relationship with age in the UCSC-based analysis (Table 4). 
In the Ensembl-based primary transcript expression ontogeny analysis of the gene set 
excluding prenatal samples, only ABCB1 (ENST00000265724) expression was significantly 
associated with age (p=0.0008) (Table 5). Group 1 (<1 year old) ABCB1 ENST00000265724 
expression differed from other age groups and expression appeared to increase with age (Figure 
4; Table 6). 
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Table 4. Total Gene mRNA Expression Ontogeny Analysis Results. 
 
Kruskal-Wallis p-value Kruskal-Wallis p-value 
 
Excluding Prenatal Including Prenatal 
Gene Ensembl UCSC  Ensembl UCSC 
ABCB1   0.0008 0.0024 <0.0001 <0.0001 
AGTR1   0.4262 0.2991 0.0315 0.4054 
AMPD1   0.4035 0.5261 0.2105 0.5888 
APOC1   0.3978 0.2023 0.0008 <0.0001 
APOC2   0.6872 0.4746 0.0480 0.0003 
APOE   0.8336 0.6200 0.6856 0.1382 
ATP2B1   0.4890 0.0246 <0.0001 <0.0001 
CETP   0.6463 0.4240 <0.0001 0.0012 
CLMN   0.9193 0.3689 0.0021 0.0019 
COQ2   0.2007 0.0443 0.0003 0.0059 
CPT2   0.4767 0.4561 0.1604 0.0121 
CYP7A1   0.0041 0.0039 <0.0001 <0.0001 
DMPK   0.0332 0.0072 <0.0001 <0.0001 
DNAJC5B   0.6655 0.1696 0.6987 0.1126 
GATM   0.7875 0.7614 0.5973 0.6912 
HMGCR   0.9994 0.9632 0.0002 0.0002 
HNRNPA1   0.9987 0.7840 <0.0001 0.0001 
HTR3B   0.8304 0.5911 0.1170 0.3277 
HTR7   0.0630 0.0377 0.0636 0.0713 
KIF6   0.0043 0.0084 <0.0001 <0.0001 
LDLR   0.5213 0.3911 0.5694 0.0973 
LPA   0.8900 0.9933 0.2358 0.0655 
LPIN1   0.1658 0.0100 0.0147 <0.0001 
MYLIP   0.6914 0.3682 <0.0001 <0.0001 
NOS3   0.9440 0.9991 0.1903 0.9723 
PCSK9   0.2771 0.1198 0.0024 0.0279 
PYGM   0.7973 0.9830 0.6099 0.9952 
RYR1   0.0993 0.0494 0.0005 0.0005 
SLC10A1   0.2400 0.1682 0.0280 0.0093 
SLCO1B1   0.6535 0.3704 0.0585 0.0018 
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Table 5. Primary Transcript Expression Ontogeny Analysis Results. 
  Kruskal-Wallis p-value Kruskal-Wallis p-value 
 
Excluding Prenatal Including Prenatal 
Transcript Ensembl UCSC  Ensembl UCSC 
ABCB1 ENST00000265724 0.0008 
 
<0.0001 
 AGTR1 ENST00000402260 or NM_032049 0.6082 0.1031 0.5421 0.2008 
AMPD1 ENST00000520113 0.6616 
 
0.4338 
 APOC1 ENST00000252491 0.3850 
 
0.0008 
 APOC2 ENST00000252490 0.7010 
 
0.0727 
 APOE ENST00000252486 0.8855 
 
0.7680 
 ATP2B1 ENST00000261173 or NM_001682 0.2835 0.3450 0.0037 0.2320 
CETP ENST00000200676 or NM_000078 0.9837 0.9450 0.0002 0.1644 
CLMN ENST00000556454 0.8287 
 
0.0003 
 COQ2 ENST00000311469 0.0174 
 
0.0002 
 CPT2 ENST00000371486 0.4943 
 
0.1418 
 DMPK ENST00000600757 or NM_001081563 0.0917 0.0134 0.0001 <0.0001 
DNAJC5B ENST00000519330 0.4474 
 
0.1457 
 GATM ENST00000396659 0.6792 
 
0.6852 
 HMGCR ENST00000287936 or NM_000859 0.9842 0.8845 0.0001 0.0002 
HNRNPA1 ENST00000547276 or NM_002136 0.9989 0.6184 0.0002 0.0001 
HTR3B ENST00000260191 0.9430 
 
0.0893 
 HTR7 ENST00000277874 or NM_000872 0.3918 0.0473 0.3699 0.0741 
KIF6 ENST00000373213 or NM_001289020 0.1453 0.0015 0.0005 <0.0001 
LDLR ENST00000252444 or NM_001195799 0.6544 0.0973 0.3915 0.0257 
LPA ENST00000316300 0.8790 
 
0.2254 
 LPIN1 ENST00000256720 or NM_145693 0.0121 0.0186 0.0002 <0.0001 
MYLIP ENST00000349606 0.6356 
 
<0.0001 
 NOS3 ENST00000297494 or NM_000603 0.9306 0.7174 0.3521 0.6297 
PCSK9 ENST00000302118 0.2274 
 
0.0051 
 PYGM ENST00000164139 or NM_001164716 0.6174 0.9177 0.7589 0.9767 
RYR1 ENST00000600337 or NM_001042723 0.3779 0.0305 0.5212 0.0041 
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Figure 2. Total Expression (Ensembl-based) of ABCB1 by Age Group. Pairwise comparison p-values presented 
above box-plots. 
 
Table 6. Mean Expression by Age Group for Genes of Significance, Excluding Prenatal 
Samples. Zero imputed for negative values in lower limit of CI. 
 
Group Mean (95% CI), TPM 
Kruskal Wallis 
p-value 
ABCB1 Total Expression 1 5.583 (3.86, 7.31) 0.0008 
 
2 9.475 (7.34, 11.61) 
 
 
3 10.545 (8.35, 12.74) 
 
 
4 12.650 (8.51, 16.79) 
 ABCB1 ENST00000265724 1 3.551 (2.31, 4.79) 0.0008 
 
2 6.696 (4.93, 8.47) 
 
 
3 7.847 (5.88, 9.81) 
 
 
4 8.899 (5.86, 11.94) 
 KIF6 NM_001289020 1 1.415 (0.50, 2.33) 0.0015 
 
2 0.008 (0, 0.02) 
 
 
3 0.025 (0. 0.05) 
 
 
4 0.036 (0, 0.12) 
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Figure 3. Total Expression (UCSC-based) of ABCB1 by Age Group. 
 
 
Figure 4. Expression (Ensembl-based) of ABCB1 Primary Transcript by Age Group. Pairwise comparison p-values 
presented above box-plots. 
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The UCSC dataset lists only one transcript for ABCB1, so an additional primary transcript 
analysis was not performed. In the UCSC dataset analysis, KIF6 NM_001289020 showed 
significant association with age (p=0.0015) (Figure 5; Table 5). KIF6 expression was highest in 
Group 1 (<1 year old), which significantly differed from other groups (Table 6). Across all age 
groups, expression of KIF6 was relatively low (< 5 TPM). 
 
 
Figure 5. Expression (UCSC-based) of KIF6 Primary Transcript by Age Group. Pairwise comparison p-values 
presented above box-plots. 
 
HMGCR and HNRNPA1 Alternative Transcript Expression  
There were no significant differences in the relative expression of alternative and 
canonical transcripts of HMGCR or HNRNPA1 (HMGCRΔ13:HMGCRex13 or 
HNRNPA1ex8:HNRNPA1Δ8) associated with HMGCR or HNRNPA1 genotypes in the general 
genetic model including the full set of liver tissue samples (Table 7). A trend toward an increase 
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in relative HMGCRΔ13 was seen with presence of ‘A’ alleles in HMGCR, but this relationship 
did not achieve significance (p=0.1015). The Caucasian subgroup general genetic model analysis 
did not show any significant trends (Table 8). 
Table 7. Alternative to Canonical Transcript Expression Ratio by Genotype, General Genetic 
Model. 
 
Genotype 
Mean Ratio (95% 
CI) 
Kruskal Wallis 
p-value 
HMGCRΔ13:HMGCRex13 rs3846662 G/G 0.294 (0.19, 0.45) 0.1015 
 
rs3846662 G/A 0.459 (0.33, 0.64) 
 
 
rs3846662 A/A 0.563 (0.33, 0.97) 
 HNRNPA1ex8:HNRNPA1Δ8 rs1920045 C/C 0.098 (0.07, 0.14) 0.5425 
 
rs1920045 C/T 0.149 (0.09, 0.26) 
 
 
rs1920045 T/T 0.112 (0.06, 0.20) 
 HMGCRΔ13:HMGCRex13 rs1920045 C/C 0.548 (0.42, 0.72) 0.1389 
 
rs1920045 C/T 0.336 (0.23, 0.50) 
 
 
rs1920045 T/T 0.373(0.17, 0.82) 
  
Table 8. Alternative to Canonical Transcript Expression Ratio by Genotype, General Genetic 
Model, Caucasian Subgroup. 
  Genotype 
Mean Ratio (95% 
CI) 
Kruskal Wallis 
p-value 
HMGCRΔ13:HMGCRex13 rs3846662 G/G 0.173 (0.05, 0.60) 0.4187 
 
rs3846662 G/A 0.273 (0.16, 0.47) 
 
 
rs3846662 A/A 0.313 (0.09, 1.14) 
 HNRNPA1ex8:HNRNPA1Δ8 rs1920045 C/C 0.087 (0.02, 0.34) 0.9232 
 
rs1920045 C/T 0.090 (0.05, 0.17) 
 
 
rs1920045 T/T 0.093 (0.00, 31.04) 
 HMGCRΔ13:HMGCRex13 rs1920045 C/C 0.427 (0.18, 1.01) 0.1359 
 
rs1920045 C/T 0.187 (0.11, 0.31) 
 
 
rs1920045 T/T 0.213 (0.08, 0.59) 
  
In the dominant genetic model including the full set of samples, expression of 
HMGCRΔ13:HMGCRex13 approached a significant association with HNRNPA1 genotype and 
HMGCR genotype (Table 9). Presence of at least one ‘T’ allele in HNRNPA1 approached an 
association with lower relative expression of HMGCRΔ13 (p=0.0470), while presence of at least 
one ‘A’ allele in HMGCR approached an association with higher relative expression of 
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HMGCRΔ13 (p=0.0465) (Figure 6,7). In the Caucasian subgroup analyses, no significant 
associations were found between genotypes and transcript expression ratios in the dominant 
model; however, the relationship between HNRNPA1 genotype and relative expression of 
HMGCRΔ13 was near significance (p=0.0500) (Table 10). 
 
Table 9. Alternative to Canonical Transcript Expression Ratio by Genotype, Dominant Genetic 
Model. 
  Genotype 
Mean Ratio (95% 
CI) 
Wilcoxon 
 p-value 
HMGCRΔ13:HMGCRex13 rs3846662 G/G 0.294 (0.19, 0.45) 0.0465 
 
rs3846662 G/A, A/A 0.491 (0.38, 0.64) 
 HNRNPA1ex8:HNRNPA1Δ8 rs1920045 C/C 0.098 (0.07,0.14) 0.3044 
 
rs1920045 C/T, T/T 0.139 (0.09, 0.21) 
 HMGCRΔ13:HMGCRex13 rs1920045 C/C 0.548 (0.42, 0.72) 0.0470 
 
rs1920045 C/T, T/T 0.345 (0.25, 0.48) 
  
 
 
Table 10. Alternative to Canonical Transcript Expression Ratio by Genotype, Dominant Genetic 
Model, Caucasian Subgroup. 
  Genotype 
Mean Ratio (95% 
CI) 
Wilcoxon 
 p-value 
HMGCRΔ13:HMGCRex13 rs3846662 G/G 0.173 (0.05, 0.60) 0.1917 
 
rs3846662 G/A, A/A 0.287 (0.19, 0.44) 
 HNRNPA1ex8:HNRNPA1Δ8 rs1920045 C/C 0.087 (0.02, 0.34) 0.7449 
 
rs1920045 C/T, T/T 0.090 (0.05, 0.15) 
 HMGCRΔ13:HMGCRex13 rs1920045 C/C 0.427 (0.18, 1.01) 0.0500 
 
rs1920045 C/T, T/T 0.192 (0.13, 0.28) 
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Figure 6. Ratio of Expression of HMGCRΔ13 to HMGCRex13 According to HMGCR Genotype, Dominant Model. 
 
 
Figure 7. Ratio of Expression of HMGCRΔ13 to HMGCRex13 According to HNRNPA1 Genotype, Dominant 
Model. 
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CPR Clinical Analysis 
Analysis of the associations between HMGCR or HNRNPA1 genotypes and lipid values in the 
CPR showed that TC and LDL-C trended toward a significant relationship with the HNRNPA1 
genotype in a general genetic model (p=0.0325 and p=0.0177, respectively) (Table 11; Figure 8, 
9). The heterozygous group had higher TC and LDL-C than either of the homozygous groups. 
No other significant associations were found in the analysis of the CPR as a whole.  
Table 11. Lipid Panel Values by Genotype, Total CPR. 
Gene, SNP Lipid Genotype 
Mean (95% CI), 
 mg/dL ANOVA p-value 
HMGCR, 
rs3846662 
TC G/G 238 (227, 250) 0.7608 
 
G/A 239 (228, 250) 
  A/A 233 (223, 243) 
LDL-C G/G 166 (156, 177) 0.1873 
 
G/A 160 (150, 171) 
  A/A 151 (143, 160) 
HDL-C G/G 44 (41, 47) 0.2546 
 
G/A 46 (43, 49) 
  A/A 48 (44, 52) 
Triglycerides G/G 124 (110, 140) 0.4066 
 
G/A 134 (119, 151) 
  A/A 142 (119, 170) 
HNRNPA1, 
rs1920045 
TC C/C 232 (221, 243) 0.0325 
 
C/T 247 (236, 258) 
  T/T 228 (216, 240) 
LDL-C C/C 153 (144, 163) 0.0177 
 
C/T 170 (160, 180) 
  T/T 151 (141, 163) 
HDL-C C/C 47 (43, 51) 0.6948 
 
C/T 46 (44, 48) 
  T/T 45 (41, 49) 
Triglycerides C/C 140 (123, 160) 0.5450 
 
C/T 132 (118, 146) 
  T/T 125 (105, 149) 
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Figure 8. Total Cholesterol Values by HNRNPA1 Genotype for All CPR Participants. Pairwise comparison p-value 
presented above box-plots. 
 
 
Figure 9. LDL Cholesterol Values by HNRNPA1 Genotype for All CPR Participants. Pairwise comparison p-value 
presented above box-plots. There was a missing value for one participant. 
 
After stratification by race, the African American subgroup showed a nearly significant 
association between HMGCR genotype with TC (p=0.0121), as well as with LDL-C (p=0.0309) 
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(Table 12; Figures 10, 11). Lipid levels trended toward an increase with the presence of the ‘A’ 
allele. Additionally, HNRNPA1 genotype showed a near significant association with TC in 
African Americans (p=0.0464) and LDL-C in Caucasians (p=0.0489) (Tables 12, 13; Figures 
12, 13). In African Americans, TC was lower in the group homozygous for the ‘T’ allele 
compared to the heterozygous group. In Caucasians, LDL-C was highest in those with only one 
‘T’ allele relative to those with either zero or two. After Bonferroni correction for multiple tests, 
the level of significance for CPR data was set at p<0.002. No relationships met this level of 
significance. There were no significant associations found between BMI category and either 
genotype before or after race stratification (Table 14). 
 
 
Figure 10. Total Cholesterol Values by HMGCR Genotype for African American CPR Participants. 
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Figure 11. LDL Cholesterol Values by HMGCR Genotype for African American CPR Participants. 
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Table 12. Lipid Panel Values by Genotype, African American Subgroup. 
Gene, SNP Lipid  Genotype 
Mean (95% CI), 
Wilcoxon p-value mg/dl 
HMGCR, 
rs3846662 
TC G/G 223 (204, 245) 0.0121 
 
G/A 283 (226, 354) 
  A/A N/A 
LDL-C G/G 156 (138, 176) 0.0309 
 
G/A 210 (145, 304) 
  A/A N/A 
HDL-C G/G 44 (39, 50) 0.3196 
 
G/A 52 (40, 69) 
  A/A N/A 
Triglycerides G/G 99 (83, 119) 0.4541 
 
G/A 79 (32, 192) 
  A/A N/A 
HNRNPA1, 
rs1920045 
TC C/C N/A 0.0464 
 
C/T 266 (222, 319) 
  T/T 224 (202, 247) 
LDL-C C/C N/A 0.1112 
 
C/T 193 (145, 258) 
  T/T 156 (137, 178) 
HDL-C C/C N/A 0.7491 
 
C/T 48 (41, 57) 
  T/T 45 (38, 52) 
Triglycerides C/C N/A 0.2474 
 
C/T 118 (84, 166)   
    T/T 88 (70, 110)   
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Figure 12. Total Cholesterol Values by HNRNPA1 Genotype for African American CPR Participants. 
 
 
 
Figure 13. LDL Cholesterol Values by HNRNPA1 Genotype for Caucasian CPR Participants. Pairwise comparison 
p-value presented above box-plots. 
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Table 13. Lipid Panel Values by Genotype, Caucasian Subgroup. 
Gene, SNP Lipid Genotype 
Mean (95% CI), Kruskal Wallis 
p-value mg/dl 
HMGCR, 
rs3846662 
TC G/G 241 (226, 256) 0.7182 
 
G/A 235 (225, 245) 
  A/A 233 (222, 243) 
LDL-C G/G 165 (153, 179) 0.3451 
 
G/A 156 (148, 165) 
  A/A 151 (142, 161) 
HDL-C G/G 45 (41, 49) 0.4428 
 
G/A 45 (43, 48) 
  A/A 47 (43, 51) 
Triglycerides G/G 137 (117, 160) 0.7097 
 
G/A 137 (120, 156) 
  A/A 145 (121, 172) 
HNRNPA1, 
rs1920045 
TC C/C 234 (223, 244) 0.5431 
 
C/T 240 (230, 250) 
  T/T 229 (213, 245) 
LDL-C C/C 155 (146, 164) 0.0489 
 
C/T 163 (155, 172) 
  T/T 146 (132, 161) 
HDL-C C/C 47 (43, 51) 0.517 
 
C/T 45 (43, 47) 
  T/T 46 (41, 51) 
Triglycerides C/C 140 (122, 160) 0.5859 
 
C/T 134 (118, 152) 
  T/T 151 (117, 196) 
 
 
 
 
 
 
 
Table 14. BMI Category by Genotype. 
Gene, SNP   
Chi-square or Fisher's 
Exact P-value   
All       
HMGCR, rs3846662 
 
0.8702 
 HNRNPA1, rs1920045*   0.1823   
Caucasians       
HMGCR, rs3846662 
 
0.6824 
 HNRNPA1, rs1920045*   0.2987   
African Americans       
HMGCR, rs3846662* 
 
0.0980 
 HNRNPA1, rs1920045* 
 
1.000 
 *Fisher's exact test was performed due to counts <5 in some cells 
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DISCUSSION 
It is widely accepted that gene expression changes during childhood growth and 
development.
1
 The study presented here set out to describe pediatric hepatic ontogeny for mRNA 
expression from 30 genes in pathways associated with cholesterol synthesis and statin response 
or toxicity, and explore the in vivo and in vitro presentation of genetic variation within two of 
these genes, HMGCR and HNRNPA1, during childhood.  
When prenatal samples were included in the analyses, many genes showed a significant 
change in expression between age groups. This was expected due to the different cellular milieu 
of the prenatal liver compared to the post-natal liver.
29
 The function of the liver changes from 
hematopoietic (maximal activity around week 15) to gluconeogenic around birth.
30
 Each of the 
genes that showed significant expression changes in the ontogeny analysis with prenatal samples 
showed, as anticipated from the literature, that the prenatal age group was the source of the 
significant difference from at least one other group (Tables B1, B2). Additionally, the significant 
gene expression changes found using the Ensembl-based data were similar to those found with 
the UCSC-based data with a few exceptions that trended toward significance in one dataset and 
achieved significance in the other: APOC2, CETP, COQ2, and LPIN1. These slight differences 
with similar trends suggest that changes in expression are occurring, but they may not be 
significant at the mRNA level. Overall, however, the results of the prenatal sample analysis 
support the biological model that hepatocyte structure and function are dynamic during gestation 
and immediately following.
29
 Since transcriptomic analysis is only a marker for clinically 
impactful biological changes, further analysis in this area should focus on gene network and 
proteomic evaluation of the genes identified in this study. 
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When prenatal samples were excluded to examine differences only between postnatal 
groups, few individual genes showed significant hepatic expression changes; however, ABCB1, 
which codes for a major drug efflux transporter, MDR1, did show an increase in mRNA 
expression with age in both the Ensembl-based total and primary transcript expression analyses 
(Table 4,6; Figures 2, 5). MDR1 is thought to transport some statins, as well as multiple non-
statin drugs, such as methotrexate, out of the liver.
16,31
 A firmer understanding of the trajectory 
of ABCB1 expression may contribute to more effective pharmacotherapy for pediatrics. For 
instance, lower levels of ABCB1 expression may indicate a time of high hepatic accumulation of 
statins, and suggest the need for a lower dose. The UCSC database includes only one possible 
transcript for ABCB1, while the Ensembl dataset includes 10. Since ABCB1 in the UCSC dataset 
showed a trend toward a significant increase in expression with age that did not achieve 
significance, further confirmation of the trend identified with the Ensembl dataset should be 
performed with a larger number of samples, focusing on the transcripts covered. The ontogenetic 
pattern found in this study supports the trend described by Mooij, et al. and further differentiates 
between the expression levels at particular developmental stages.
19
 A proteomic study of hepatic 
MDR1 expression and activity could elucidate the functional implications of this mRNA 
expression change. Furthermore, although few individual genes showed significant expression 
changes with age, the sum of individually small changes may be acting in a network to affect the 
pathways associated with cholesterol metabolism and statin therapeutic response and toxicity. 
For this reason, gene network analysis should be performed with the RNA-seq dataset as the next 
step in examination of this dataset. 
The associations between HMGCR (rs3846662) or HNRNPA1 (rs1920045) genotype and 
the relative expression of alternative and canonical transcripts of HMGCR and HNRNPA1 were 
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not found to be statistically significant in the pediatric liver samples. Burkhardt, et al. described 
how HMGCRΔ13 relative expression was increased in cells carrying an HMGCR ‘A’ allele in 
LCLs. Our results showed a trend of increased relative HMGCRΔ13 expression in pediatric liver 
samples that did not achieve statistical significance in either the general genetic or dominant 
HMGCR model. Yu, et al. described that the ‘T’ allele upstream of HNRNPA1 is associated with 
altered constitutive expression of HNRNPA1ex8 in LCLs (Yu, et al. Supplemental Figure S6-A). 
Neither the general genetic model nor the dominant model supported an expression association 
between HNRNPA1 genotype and relative expression of HNRNPA1ex8 in pediatric livers 
(Tables 7, 9). It was hypothesized that the ‘T’ allele should be expected to be associated with a 
decrease in constitutive relative HMGCRΔ13. No significant expression differences were 
detected between HNRNPA1 genotype groups in the general genetic model, suggesting that, in 
pediatric hepatocytes, the associations are not strong. The dominant HNRNPA1 genetic model, 
however, did show a trend toward a significant expression change, with decreased HMGCRΔ13 
expression in the presence of one or two ‘T’ alleles, in line with the hypothesized effect. This 
result suggests that the hypothesized relationship between rs1920045 and HMGCR expression 
may be present in the pediatric population, but should be confirmed in a larger set of samples. 
The allele frequencies for both genotypes differ by race, which led to the decision to stratify the 
results by this factor. The dbSNP published frequencies of the HMGCR ‘G’ alleles in Caucasians 
and African Americans (population AoD) are 0.40 and 0.86, respectively.  The dbSNP published 
frequencies of HNRNPA1 ‘C’ alleles in Caucasians and African Americans (population AoD) are 
0.63 and 0.29, respectively.  In the Caucasian subgroup analyses, no significant associations 
between genotype and expression were found in either model. Analysis of the African American 
subgroup was not possible due to limited sample size. There are some limitations to our 
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genotype-associated expression analysis. The small sample size may have caused the race 
stratification analysis to be underpowered, thus masking significant trends.  Additionally, the 
samples in this study spanned multiple developmental ages, however, small samples in each 
age/genotype group precluded stratification analysis. Preliminary investigation into the relative 
expression of HMGCRΔ13 across developmental ages trended toward, but did not reach 
significance, showing the need for further studies on the relationship between age and this 
expression (data not shown). An expansion of the sample size to include better representation of 
racial groups and developmental ages should be pursued in order to further evaluate the 
relationship between expression and genotype in children. 
Evaluation of the relationships between HMGCR (rs3846662) and HNRNPA1 
(rs1920045) genotypes and in vivo lipid levels revealed interesting associations. Based on adult 
studies and cell models, the HMGCR ‘A’ and HNRNPA1 ‘C’ alleles were anticipated to be 
associated with lower baseline total and LDL cholesterol values.
2,24
 In the CPR sample evaluated 
as a whole, no association was seen between baseline cholesterol values and HMGCR genotype. 
Near significant associations between HNRNPA1 genotype and TC or LDL-C were found. In 
both cases, the heterozygous group had higher TC and LDL-C values than either of the 
homozygous groups. Since the group showing different expression was heterozygous, this 
finding was inconclusive. Once the cohort was stratified by race, some of the associations 
between lipid panel values and genotype changed. The Caucasian subgroup analysis did not 
reveal any significant relationships between genotypes and age, although the relationship 
between LDL-C and HNRNPA1 genotype approached significance, with the same pattern of 
highest LDL-C values in the heterozygous group. In the African American subgroup, the 
relationships between HMGCR genotype and TC or LDL-C trended toward significance and 
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average levels increased with the presence of one ‘A’ allele. This was opposite of the expected 
relationship. Additionally, a trend toward a significant decrease in TC with the presence of the 
HNRNPA1 ‘T’ allele was noted. After the Bonferroni correction for multiple tests, no 
relationships met the criteria for significance, yet this is considered to be an overly-conservative 
adjustment for significance. The data showed preliminary evidence for interesting trends 
between HMGCR or HNRNPA1 genotypes and lipid levels in children and revealed that race 
may be confounding the genotype-phenotype relationship.  This information indicated that 
further studies should focus on ensuring adequate representation of racial groups when 
characterizing the clinical implications of these SNPs in pediatrics. An additional limitation in 
the evaluation of in vivo lipid levels was that the study group overall had higher lipid levels than 
average, and there was no comparison to a group of children with “acceptable” lipid levels. 
Further investigations into this, and into trends in lipid levels over time, may better elucidate the 
relationship between lipid levels and these genotypes. One additional limitation is in the race 
stratification. Using self-reported race may not be as accurate as identifying race by genotyping, 
and including individuals reporting Hispanic ethnicity within their respective racial group, 
without stratification, may mask some relationships that could be present. 
In conclusion, this study confirmed the presence of dynamic gene expression in the liver 
during childhood development; however the number of genes with expression changes after birth 
was less than anticipated. For this study, and many others, mRNA was used as a surrogate 
marker to investigate downstream changes, such as protein expression. Since mRNA is not 
translated at a universal rate and can be differentially degraded, the lack of mRNA expression 
changes in the pediatric hepatocytes may not actually indicate constant expression of transporter 
proteins or enzymes. Future studies should focus on protein activity changes throughout 
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development. In particular, the implications of ABCB1 mRNA expression increasing with age 
should be evaluated on a protein level, as the MDR1 transporter is involved with multiple 
medications, and this knowledge could contribute to pharmacokinetic models.  
Furthermore, the information in this study suggests that the impact of genetic variation in 
pediatrics may not mimic that of adult relationships. Genotype-phenotype relationships that are 
significant in adult populations may not be significant in children, or the relationships may be 
altered. Our study showed that the expression changes associated with two SNPs in LCLs were 
not significant in pediatric hepatocytes, but certain relationships trended toward significance. In 
vivo, the impact of these SNPs appeared to be confounded by race. Relationships approaching 
significance appeared after stratification, including two with phenotypes opposite of what had 
been hypothesized.  
The challenges of establishing adequate sample sizes for full genomic studies in the 
pediatric setting highlights the importance of maximizing that data from each study. The 
indication that race and age may confound phenotypic presentation in individuals from this study 
points to the need to ensure adequate representation of different races and developmental stages 
in future pediatric pharmacogenomic studies. 
When possible, data on established genotype-phenotype relationships from adult studies 
should be utilized to inform therapeutic interventions in children; however, only studies 
conducted in pediatric populations will accurately capture variability attributable to maturity, 
which is not evident from adult studies.  
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APPENDIX A 
List of Gene Abbreviations 
ABCB1 – ATP-Binding Cassette, Sub-Family B, Member 1 
AGTR1 – Angiotensin II Receptor, Type 1 
AMPD1 – Adenosine Monophosphate Deaminase 1 
APOC1 – Apolipoprotein C-I 
APOC2 – Apolipoprotein C-II 
APOE – Apolipoprotein E 
ATP2B1 – ATPase, Ca++ Transporting, Plasma Membrane 1 
CETP – Cholesterol Ester Transfer Protein, plasma 
CLMN – Calmin 
CPT2 – Carnitine Palmitoyltransferase 2 
COQ2 – Coenzyme Q2 4-hydroxybenzoate Polyprenyltransferase 
CYP7A1 – Cytochrome P450, Family 7, Subfamily A, Polypeptide 1 
DMPK – Dystrophia Myotonica-protein Kinase 
DNAJC5B – DnaJ(Hsp40) homolog, Subfamily C, Member 5 Beta 
GATM – Glycine Amidinotransferase 
HMGCR – 3-Hydroxy-3-methylglutaryl CoA Reductase 
HNRNPA1 – Heterogeneous Nuclear Ribonucleoprotein A1 
HTR3B – 5-Hydroxytryptamine Receptor 3B, Ionotropic 
HTR7 – 5-Hydroxytrptamine Receptor 7, Adenylate Cyclase-coupled 
KIF6 – Kinesin Family Member 6 
LDLR – Low Density Lipoprotein Receptor 
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LPA – Lipoprotein, Lp(a) 
LPIN1 – Lipin 1 
MDR1* – Multidrug Resistance Protein 1 
MYLIP – Myosin Regulatory Light Chain Interacting Protein 
NOS3 – Nitric Oxide Synthase 3 
PCSK9 – Proprotein Convertase Subtilisin/Kexin Type 9 
PYGM –Phosphorylase, Glycogen, Muscle 
RYR1 – Ryanodine Receptor 1 
SLC10A1 – Solute Carrier Family 10, Member 1 
SLCO1B1 – Solute Carrier Organic Anion Transporter Family, Member 1B1 
*Protein, not gene 
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APPENDIX B 
Table B1. Pairwise Comparison Results for Total Gene Expression with Prenatal Samples by Age Group Analysis. 
 
 
Gene 
Ensembl 
Comparison 
 
p-value 
UCSC 
Comparison 
 
p-value 
ABCB1 Group 2 Group 0 0.0013 Group 2 Group 0 0.0003 
ABCB1 Group 3 Group 0 0.0006 Group 3 Group 0 0.0006 
ABCB1 Group 3 Group 1 0.0093 Group 1 Group 0 0.0009 
ABCB1 Group 2 Group 1 0.0356 Group 3 Group 1 0.0275 
ABCB1 Group 4 Group 1 0.0131 Group 4 Group 1 0.0163 
ABCB1 Group 4 Group 0 0.0041 Group 4 Group 0 0.0041 
ABCB1 Group 1 Group 0 0.1232 Group 2 Group 1 0.1425 
ABCB1 Group 4 Group 3 0.7113 Group 4 Group 2 0.5622 
ABCB1 Group 4 Group 2 0.8211 Group 4 Group 3 0.6198 
ABCB1 Group 3 Group 2 0.9399 Group 3 Group 2 0.9692 
APOC1 Group 3 Group 0 0.0006 Group 2 Group 0 0.0003 
APOC1 Group 2 Group 0 0.0125 Group 3 Group 0 0.0006 
APOC1 Group 4 Group 0 0.0056 Group 1 Group 0 0.0045 
APOC1 Group 1 Group 0 0.0805 Group 4 Group 0 0.0041 
APOC1 Group 3 Group 2 0.5540 Group 3 Group 2 0.4140 
APOC1 Group 3 Group 1 0.9657 Group 4 Group 2 0.9999 
APOC1 Group 4 Group 2 0.9999 Group 3 Group 1 1.0000 
APOC1 Group 4 Group 1 0.9528 Group 4 Group 3 0.8654 
APOC1 Group 2 Group 1 0.9395 Group 4 Group 1 0.7547 
APOC1 Group 4 Group 3 0.7113 Group 2 Group 1 0.4441 
APOC2   Group 2 Group 0 0.0034 
APOC2   Group 1 Group 0 0.0029 
APOC2   Group 3 Group 0 0.0042 
APOC2   Group 4 Group 0 0.0041 
APOC2   Group 3 Group 2 0.9131 
APOC2   Group 4 Group 2 0.9778 
APOC2   Group 3 Group 1 0.9865 
APOC2   Group 4 Group 3 0.9205 
APOC2   Group 2 Group 1 0.7835 
APOC2   Group 4 Group 1 0.6719 
ATP2B1 Group 3 Group 2 0.9986 Group 3 Group 2 0.4411 
ATP2B1 Group 3 Group 1 0.9963 Group 4 Group 2 0.9853 
ATP2B1 Group 2 Group 1 0.9275 Group 3 Group 1 0.7436 
ATP2B1 Group 4 Group 3 0.8315 Group 4 Group 3 0.4327 
ATP2B1 Group 4 Group 2 0.8212 Group 4 Group 1 0.1991 
ATP2B1 Group 4 Group 1 0.6719 Group 2 Group 1 0.1179 
ATP2B1 Group 4 Group 0 0.0041 Group 4 Group 0 0.0041 
ATP2B1 Group 1 Group 0 0.0012 Group 1 Group 0 0.0180 
ATP2B1 Group 3 Group 0 0.0008 Group 3 Group 0 0.0006 
ATP2B1 Group 2 Group 0 0.0003 Group 2 Group 0 0.0003 
CETP Group 4 Group 2 0.8362 Group 4 Group 2 0.6023 
CETP Group 4 Group 3 0.9205 Group 4 Group 3 0.6662 
CETP Group 3 Group 2 0.9609 Group 4 Group 1 0.7926 
CETP Group 4 Group 1 0.9958 Group 3 Group 2 0.9959 
CETP Group 3 Group 1 1.0000 Group 3 Group 1 0.9979 
CETP Group 2 Group 1 0.9141 Group 2 Group 1 0.9747 
CETP Group 4 Group 0 0.0041 Group 4 Group 0 0.4138 
CETP Group 1 Group 0 0.0015 Group 1 Group 0 0.0083 
CETP Group 3 Group 0 0.0008 Group 3 Group 0 0.0052 
CETP Group 2 Group 0 0.0007 Group 2 Group 0 0.0034 
 
  
   
   43 
Table B1. Pairwise Comparison Results for Total Gene Expression with Prenatal Samples Continued. 
 
Gene 
Ensembl 
Comparison 
 
p-value 
UCSC 
Comparison 
 
p-value 
COQ2 Group 3 Group 1 0.3617   
COQ2 Group 3 Group 2 0.4409   
COQ2 Group 4 Group 1 0.7547   
COQ2 Group 4 Group 2 0.9015   
COQ2 Group 2 Group 1 1.0000   
COQ2 Group 4 Group 3 0.9985   
COQ2 Group 4 Group 0 0.3610   
COQ2 Group 3 Group 0 0.1024   
COQ2 Group 1 Group 0 0.0005   
COQ2 Group 2 Group 0 0.0004   
CYP7A1 Group 1 Group 0 0.0008 Group 1 Group 0 0.0009 
CYP7A1 Group 3 Group 0 0.0007 Group 3 Group 0 0.0034 
CYP7A1 Group 2 Group 0 0.0321 Group 4 Group 0 0.0132 
CYP7A1 Group 4 Group 0 0.0082 Group 2 Group 0 0.0976 
CYP7A1 Group 3 Group 2 0.2461 Group 3 Group 2 0.5369 
CYP7A1 Group 4 Group 2 0.9220 Group 4 Group 2 0.8889 
CYP7A1 Group 4 Group 3 0.9417 Group 4 Group 3 0.9828 
CYP7A1 Group 4 Group 1 0.3882 Group 4 Group 1 0.2934 
CYP7A1 Group 3 Group 1 0.2828 Group 3 Group 1 0.1857 
CYP7A1 Group 2 Group 1 0.0072 Group 2 Group 1 0.0054 
DMPK Group 4 Group 3 0.8319 Group 4 Group 3 0.9947 
DMPK Group 4 Group 2 1.0000 Group 4 Group 2 0.8898 
DMPK Group 4 Group 1 0.4948 Group 3 Group 2 0.5540 
DMPK Group 3 Group 2 0.5827 Group 2 Group 1 0.4055 
DMPK Group 2 Group 1 0.5104 Group 1 Group 0 0.2293 
DMPK Group 4 Group 0 0.0077 Group 4 Group 1 0.0780 
DMPK Group 3 Group 1 0.0420 Group 4 Group 0 0.0041 
DMPK Group 1 Group 0 0.0258 Group 3 Group 1 0.0151 
DMPK Group 3 Group 0 0.0006 Group 2 Group 0 0.0061 
DMPK Group 2 Group 0 0.0013 Group 3 Group 0 0.0006 
HMGCR Group 2 Group 1 1.0000 Group 2 Group 1 0.9967 
HMGCR Group 4 Group 1 1.0000 Group 3 Group 2 1.0000 
HMGCR Group 3 Group 1 1.0000 Group 4 Group 1 1.0000 
HMGCR Group 3 Group 2 1.0000 Group 3 Group 1 1.0000 
HMGCR Group 4 Group 2 1.0000 Group 4 Group 3 0.9947 
HMGCR Group 4 Group 3 1.0000 Group 4 Group 2 0.9778 
HMGCR Group 4 Group 0 0.0077 Group 4 Group 0 0.0139 
HMGCR Group 2 Group 0 0.0023 Group 3 Group 0 0.0008 
HMGCR Group 3 Group 0 0.0006 Group 2 Group 0 0.0023 
HMGCR Group 1 Group 0 0.0005 Group 1 Group 0 0.0006 
HNRNPA1 Group 4 Group 1 1.0000 Group 3 Group 2 1.0000 
HNRNPA1 Group 3 Group 2 1.0000 Group 4 Group 2 0.9999 
HNRNPA1 Group 4 Group 2 1.0000 Group 4 Group 3 0.9947 
HNRNPA1 Group 3 Group 1 1.0000 Group 3 Group 1 0.9907 
HNRNPA1 Group 2 Group 1 0.9997 Group 2 Group 1 0.9502 
HNRNPA1 Group 4 Group 3 0.9976 Group 4 Group 1 0.8280 
HNRNPA1 Group 4 Group 0 0.0041 Group 4 Group 0 0.0041 
HNRNPA1 Group 3 Group 0 0.0006 Group 2 Group 0 0.0023 
HNRNPA1 Group 1 Group 0 0.0005 Group 3 Group 0 0.0006 
HNRNPA1 Group 2 Group 0 0.0004 Group 1 Group 0 0.0005 
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Table B1. Pairwise Comparison Results for Total Gene Expression with Prenatal Samples Continued. 
 
Gene 
Ensembl 
Comparison 
 
p-value 
UCSC 
Comparison 
 
p-value 
KIF6 Group 4 Group 3 0.9985 Group 3 Group 2 0.8655 
KIF6 Group 3 Group 2 0.9998 Group 4 Group 2 0.9988 
KIF6 Group 4 Group 2 0.9999 Group 4 Group 3 0.8002 
KIF6 Group 4 Group 1 0.1004 Group 4 Group 1 0.1241 
KIF6 Group 4 Group 0 0.0041 Group 3 Group 1 0.1157 
KIF6 Group 3 Group 1 0.0204 Group 2 Group 1 0.0412 
KIF6 Group 2 Group 1 0.0245 Group 4 Group 0 0.0036 
KIF6 Group 3 Group 0 0.0006 Group 1 Group 0 0.0035 
KIF6 Group 1 Group 0 0.0007 Group 3 Group 0 0.0006 
KIF6 Group 2 Group 0 0.0003 Group 2 Group 0 0.0002 
LPIN1   Group 2 Group 0 0.0003 
LPIN1   Group 3 Group 0 0.0008 
LPIN1   Group 1 Group 0 0.0023 
LPIN1   Group 2 Group 1 0.0357 
LPIN1   Group 4 Group 0 0.0836 
LPIN1   Group 3 Group 1 0.2592 
LPIN1   Group 4 Group 1 0.9996 
LPIN1   Group 3 Group 2 0.8974 
LPIN1   Group 4 Group 3 0.3886 
LPIN1   Group 4 Group 2 0.1896 
MYLIP Group 4 Group 3 1.0000 Group 4 Group 3 1.0000 
MYLIP Group 3 Group 2 1.0000 Group 3 Group 2 1.0000 
MYLIP Group 3 Group 1 0.9374 Group 4 Group 2 0.9122 
MYLIP Group 2 Group 1 0.9274 Group 4 Group 1 0.7921 
MYLIP Group 4 Group 1 0.8747 Group 3 Group 1 0.6385 
MYLIP Group 4 Group 2 0.8774 Group 2 Group 1 0.6053 
MYLIP Group 4 Group 0 0.0041 Group 4 Group 0 0.0041 
MYLIP Group 3 Group 0 0.0006 Group 1 Group 0 0.0009 
MYLIP Group 1 Group 0 0.0005 Group 3 Group 0 0.0006 
MYLIP Group 2 Group 0 0.0003 Group 2 Group 0 0.0003 
RYR1 Group 4 Group 3 1.0000 Group 3 Group 2 0.9920 
RYR1 Group 4 Group 2 0.9614 Group 4 Group 3 0.9856 
RYR1 Group 3 Group 2 0.8596 Group 4 Group 2 0.8949 
RYR1 Group 2 Group 1 0.8352 Group 4 Group 1 0.4009 
RYR1 Group 4 Group 1 0.3459 Group 1 Group 0 0.3445 
RYR1 Group 1 Group 0 0.0862 Group 4 Group 0 0.1008 
RYR1 Group 3 Group 1 0.1070 Group 2 Group 1 0.1800 
RYR1 Group 4 Group 0 0.0185 Group 3 Group 1 0.1315 
RYR1 Group 2 Group 0 0.0186 Group 3 Group 0 0.0057 
RYR1 Group 3 Group 0 0.0029 Group 2 Group 0 0.0026 
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Table B2. Pairwise Comparison Results for Primary Transcript Expression with Prenatal Samples by Age Group 
Analysis. 
 
 
Transcript 
Ensembl 
Comparison 
 
p-value 
UCSC 
Comparison 
 
p-value 
ABCB1 ENST00000265724 Group 2 Group 0 0.0013   
ABCB1 ENST00000265724 Group 3 Group 0 0.0006   
ABCB1 ENST00000265724 Group 3 Group 1 0.0040   
ABCB1 ENST00000265724 Group 4 Group 1 0.0131   
ABCB1 ENST00000265724 Group 4 Group 0 0.0041   
ABCB1 ENST00000265724 Group 2 Group 1 0.0707   
ABCB1 ENST00000265724 Group 1 Group 0 0.2043   
ABCB1 ENST00000265724 Group 4 Group 2 0.7368   
ABCB1 ENST00000265724 Group 3 Group 2 0.9511   
ABCB1 ENST00000265724 Group 4 Group 3 0.9591   
APOC1 ENST00000252491 Group 3 Group 0 0.0006   
APOC1 ENST00000252491 Group 2 Group 0 0.0125   
APOC1 ENST00000252491 Group 4 Group 0 0.0056   
APOC1 ENST00000252491 Group 1 Group 0 0.0805   
APOC1 ENST00000252491 Group 3 Group 2 0.5254   
APOC1 ENST00000252491 Group 3 Group 1 0.9557   
APOC1 ENST00000252491 Group 4 Group 2 0.9995   
APOC1 ENST00000252491 Group 4 Group 1 0.9528   
APOC1 ENST00000252491 Group 2 Group 1 0.9502   
APOC1 ENST00000252491 Group 4 Group 3 0.7113   
CETP ENST00000200676 Group 4 Group 2 0.9909   
CETP ENST00000200676 Group 4 Group 3 0.9991   
CETP ENST00000200676 Group 2 Group 1 1.0000   
CETP ENST00000200676 Group 3 Group 2 1.0000   
CETP ENST00000200676 Group 4 Group 1 1.0000   
CETP ENST00000200676 Group 3 Group 1 0.9923   
CETP ENST00000200676 Group 4 Group 0 0.0041   
CETP ENST00000200676 Group 3 Group 0 0.0013   
CETP ENST00000200676 Group 1 Group 0 0.0015   
CETP ENST00000200676 Group 2 Group 0 0.0017   
CLMN ENST00000556454 Group 3 Group 0 0.0008   
CLMN ENST00000556454 Group 1 Group 0 0.0015   
CLMN ENST00000556454 Group 2 Group 0 0.0038   
CLMN ENST00000556454 Group 4 Group 0 0.0139   
CLMN ENST00000556454 Group 3 Group 2 1.0000   
CLMN ENST00000556454 Group 4 Group 2 1.0000   
CLMN ENST00000556454 Group 4 Group 3 0.9998   
CLMN ENST00000556454 Group 3 Group 1 0.9557   
CLMN ENST00000556454 Group 2 Group 1 0.9596   
CLMN ENST00000556454 Group 4 Group 1 0.9351   
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Table B2. Pairwise Comparison Results for Primary Transcript Expression Continued with Prenatal Samples. 
 
 
Ensembl UCSC 
Transcript Comparison p-value Comparison p-value 
COQ2 ENST00000311469 Group 3 Group 1 0.1405   
COQ2 ENST00000311469 Group 3 Group 2 0.2042   
COQ2 ENST00000311469 Group 4 Group 2 0.2087   
COQ2 ENST00000311469 Group 4 Group 1 0.1696   
COQ2 ENST00000311469 Group 2 Group 1 0.9994   
COQ2 ENST00000311469 Group 4 Group 3 1.0000   
COQ2 ENST00000311469 Group 4 Group 0 0.5266   
COQ2 ENST00000311469 Group 3 Group 0 0.4695   
COQ2 ENST00000311469 Group 2 Group 0 0.0033   
COQ2 ENST00000311469 Group 1 Group 0 0.0006   
DMPK ENST00000600757 or NM_001081563 Group 4 Group 3 0.9997 Group 4 Group 3 0.9995 
DMPK ENST00000600757 or NM_001081563 Group 3 Group 2 0.9999 Group 4 Group 2 0.9997 
DMPK ENST00000600757 or NM_001081563 Group 4 Group 2 1.0000 Group 3 Group 2 0.9997 
DMPK ENST00000600757 or NM_001081563 Group 4 Group 1 0.3770 Group 1 Group 0 0.6052 
DMPK ENST00000600757 or NM_001081563 Group 3 Group 1 0.2505 Group 4 Group 1 0.1373 
DMPK ENST00000600757 or NM_001081563 Group 2 Group 1 0.2387 Group 4 Group 0 0.0184 
DMPK ENST00000600757 or NM_001081563 Group 1 Group 0 0.0923 Group 2 Group 1 0.0965 
DMPK ENST00000600757 or NM_001081563 Group 4 Group 0 0.0131 Group 3 Group 1 0.0340 
DMPK ENST00000600757 or NM_001081563 Group 3 Group 0 0.0025 Group 3 Group 0 0.0016 
DMPK ENST00000600757 or NM_001081563 Group 2 Group 0 0.0014 Group 2 Group 0 0.0042 
HMGCR ENST00000287936 or NM_000859 Group 3 Group 2 0.9999 Group 4 Group 3 0.9828 
HMGCR ENST00000287936 or NM_000859 Group 2 Group 1 1.0000 Group 4 Group 2 0.9995 
HMGCR ENST00000287936 or NM_000859 Group 3 Group 1 1.0000 Group 4 Group 1 0.9998 
HMGCR ENST00000287936 or NM_000859 Group 4 Group 1 0.9998 Group 2 Group 1 0.9984 
HMGCR ENST00000287936 or NM_000859 Group 4 Group 2 0.9972 Group 3 Group 2 0.9968 
HMGCR ENST00000287936 or NM_000859 Group 4 Group 3 0.9947 Group 3 Group 1 0.9374 
HMGCR ENST00000287936 or NM_000859 Group 4 Group 0 0.0056 Group 4 Group 0 0.0104 
HMGCR ENST00000287936 or NM_000859 Group 3 Group 0 0.0006 Group 1 Group 0 0.0019 
HMGCR ENST00000287936 or NM_000859 Group 2 Group 0 0.0019 Group 3 Group 0 0.0006 
HMGCR ENST00000287936 or NM_000859 Group 1 Group 0 0.0005 Group 2 Group 0 0.0015 
HNRNPA1 ENST00000547276 or NM_002136 Group 4 Group 1 0.9981 Group 3 Group 2 0.9959 
HNRNPA1 ENST00000547276 or NM_002136 Group 3 Group 2 0.9997 Group 4 Group 2 0.9947 
HNRNPA1 ENST00000547276 or NM_002136 Group 4 Group 2 1.0000 Group 3 Group 1 0.9907 
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Table B2. Pairwise Comparison Results for Primary Transcript Expression Continued with Prenatal Samples. 
 Ensembl  UCSC  
Transcript Comparison p-value Comparison p-value 
HNRNPA1 ENST00000547276 or NM_002136 Group 4 Group 3 1.0000 Group 4 Group 3 0.9418 
HNRNPA1 ENST00000547276 or NM_002136 Group 2 Group 1 1.0000 Group 4 Group 1 0.8280 
HNRNPA1 ENST00000547276 or NM_002136 Group 3 Group 1 0.9989 Group 2 Group 1 0.8270 
HNRNPA1 ENST00000547276 or NM_002136 Group 4 Group 0 0.0041 Group 4 Group 0 0.0041 
HNRNPA1 ENST00000547276 or NM_002136 Group 3 Group 0 0.0010 Group 3 Group 0 0.0010 
HNRNPA1 ENST00000547276 or NM_002136 Group 1 Group 0 0.0009 Group 2 Group 0 0.0028 
HNRNPA1 ENST00000547276 or NM_002136 Group 2 Group 0 0.0019 Group 1 Group 0 0.0005 
KIF6 ENST00000373213 or NM_001289020 Group 3 Group 2  Group 3 Group 2 0.7470 
KIF6 ENST00000373213 or NM_001289020 Group 4 Group 2  Group 4 Group 2 1.0000 
KIF6 ENST00000373213 or NM_001289020 Group 4 Group 3  Group 4 Group 3 0.9612 
KIF6 ENST00000373213 or NM_001289020 Group 4 Group 1 0.8435 Group 4 Group 1 0.1000 
KIF6 ENST00000373213 or NM_001289020 Group 3 Group 1 0.6691 Group 3 Group 1 0.0883 
KIF6 ENST00000373213 or NM_001289020 Group 2 Group 1 0.5692 Group 4 Group 0 0.0028 
KIF6 ENST00000373213 or NM_001289020 Group 4 Group 0 0.1823 Group 2 Group 1 0.0120 
KIF6 ENST00000373213 or NM_001289020 Group 1 Group 0 0.2298 Group 1 Group 0 0.0034 
KIF6 ENST00000373213 or NM_001289020 Group 3 Group 0 0.0472 Group 3 Group 0 0.0004 
KIF6 ENST00000373213 or NM_001289020 Group 2 Group 0 0.0210 Group 2 Group 0 <0.0001 
LPIN1 ENST00000256720 or  NM_145693 Group 2 Group 0 0.0028 Group 2 Group 0 0.0003 
LPIN1 ENST00000256720 or  NM_145693 Group 3 Group 0 0.0122 Group 3 Group 0 0.0008 
LPIN1 ENST00000256720 or  NM_145693 Group 2 Group 1 0.0567 Group 1 Group 0 0.0092 
LPIN1 ENST00000256720 or  NM_145693 Group 3 Group 1 0.0549 Group 2 Group 1 0.0634 
LPIN1 ENST00000256720 or  NM_145693 Group 1 Group 0 0.2850 Group 4 Group 0 0.0317 
LPIN1 ENST00000256720 or  NM_145693 Group 4 Group 0 0.1713 Group 3 Group 1 0.2592 
LPIN1 ENST00000256720 or  NM_145693 Group 4 Group 1 0.9958 Group 4 Group 1 1.0000 
LPIN1 ENST00000256720 or  NM_145693 Group 3 Group 2 1.0000 Group 3 Group 2 0.9399 
LPIN1 ENST00000256720 or  NM_145693 Group 4 Group 2 0.5420 Group 4 Group 3 0.3886 
LPIN1 ENST00000256720 or  NM_145693 Group 4 Group 3 0.3886 Group 4 Group 2 0.3018 
MYLIP ENST00000349606 Group 3 Group 2 0.9923    
MYLIP ENST00000349606 Group 4 Group 2 1.0000    
MYLIP ENST00000349606 Group 4 Group 3 0.9991    
MYLIP ENST00000349606 Group 3 Group 1 0.9839    
MYLIP ENST00000349606 Group 4 Group 1 0.8887    
MYLIP ENST00000349606 Group 2 Group 1 0.7107    
MYLIP ENST00000349606 Group 4 Group 0 0.0041    
MYLIP ENST00000349606 Group 3 Group 0 0.0006    
MYLIP ENST00000349606 Group 1 Group 0 0.0006    
MYLIP ENST00000349606 Group 2 Group 0 0.0003    
 
 
 
